The effect of the AN69 ST100 versus oXiris^® membrane on filter life during CRRT for non-anticoagulated liver failure patients.

Abstract

Backgrounds: In patients with liver failure, continuous renal replacement therapy (CRRT) without anticoagulation may be necessary. A new heparin coated membrane (oXiris®) may prolong circuit life in this setting. Objectives: In liver failure patients not receiving anticoagulation, to compare CRRT circuit life with the oXiris® versus the AN69 ST100 (usual care) membrane. Methods: Randomized single cross-over trial. Results: We studied 20 patients and 39 circuits. Twenty-five treatments used femoral and 14 internal jugular access catheters. Median circuit life was 21 h (IQR: 8.25–35.5) with the AN69 versus 16.0 h (14–25) with the oXiris® membrane (p = 0.36). Median first circuit duration was 14 (11.25–23) h for the AN69 ST100 versus 16 (8 –26) for the oXiris® membrane. There was also no difference between the AN69 ST100 or oXiris® membrane circuits using femoral access at 13 (8 –22.5) versus 15.5 (12.5–21.5) h (p = 0.57) or internal jugular access at 28 (13–47) versus 23 (21–29) h (p = 0.79), respectively. Conclusions: The oXiris® heparin-grafted membrane does not appear to prolong circuit life in liver failure patients receiving CRRT without anticoagulation.